PSUSA/00002042/202507
Submitted by Anonymous (not verified) on 7 April 2026 - 15:35
PSUSA/00002042/202507
PSUSA/00002661/202507
Submitted by Anonymous (not verified) on 7 April 2026 - 15:28
PSUSA/00002661/202507
Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 37, Status: Authorised
Submitted by Anonymous (not verified) on 7 April 2026 - 15:06
Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 37, Status: Authorised
Human medicines European public assessment report (EPAR): Aerinaze, desloratadine,pseudoephedrine, Date of authorisation: 30/07/2007, Revision: 23, Status: Authorised
Submitted by Anonymous (not verified) on 7 April 2026 - 14:24
Human medicines European public assessment report (EPAR): Aerinaze, desloratadine,pseudoephedrine, Date of authorisation: 30/07/2007, Revision: 23, Status: Authorised
Public engagement highlights 2025
Submitted by Anonymous (not verified) on 7 April 2026 - 14:18
Public engagement highlights 2025
Human medicines European public assessment report (EPAR): Zokinvy, lonafarnib, Date of authorisation: 18/07/2022, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 7 April 2026 - 14:16
Human medicines European public assessment report (EPAR): Zokinvy, lonafarnib, Date of authorisation: 18/07/2022, Revision: 4, Status: Authorised
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 April 2026, European Medicines Agency, Amsterdam, the Netherlands, from 7 April 2026 to 10 April 2026
Submitted by Anonymous (not verified) on 7 April 2026 - 13:46
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 April 2026, European Medicines Agency, Amsterdam, the Netherlands, from 7 April 2026 to 10 April 2026
European Medicines Agency's data protection notice for the implementation of the Instrument for Pre-accession Assistance (IPA) programme
Submitted by Anonymous (not verified) on 7 April 2026 - 12:36
European Medicines Agency's data protection notice for the implementation of the Instrument for Pre-accession Assistance (IPA) programme
SPOR and XEVMPD status update webinar - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 April 2026, 10:00 (CEST) to 13 April 2026, 12:30 (CEST)
Submitted by Anonymous (not verified) on 7 April 2026 - 12:36
SPOR and XEVMPD status update webinar - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 April 2026, 10:00 (CEST) to 13 April 2026, 12:30 (CEST)
Industry Standing Group
Submitted by Anonymous (not verified) on 7 April 2026 - 12:33
Industry Standing Group